Healthcare

● Few names capture the promise and the peril of computational drug discovery as sharply as Recursion Pharmaceuticals.

Rockwell Medical, Inc (NASDAQ:RMTI) has spent 2026 reshaping itself, and the market is still deciding how to price the result. After a reverse stock split, a restored Nasdaq listing standing and a revenue base in transition, shares of the dialysis-products supplier have drifted modestly …

A quoted 99% drop looks catastrophic until you notice the arithmetic behind it. Redwood Scientific Technologies, Inc. (OTC:RSCI) trades in ten-thousandths of a dollar, a realm where a move from just over a penny to the $0.0001 minimum tick registers as a near-total wipeout …

The Q appended to RVLPQ tells much of the story. RVL Pharmaceuticals plc (OTC:RVLPQ), the specialty-pharma company behind Upneeq, an eyedrop for droopy eyelids, now trades at a fraction of a cent under a ticker whose suffix conventionally signals bankruptcy or severe distress.

Few diagnostics stocks have had a rougher stretch than QuidelOrtho Corporation (NASDAQ:QDEL). Once a pandemic-era testing darling, the company has watched its shares slide from a 52-week high near $35.58 to around $12.64, and a recent daily drop keeps the pressure squarely on management's …

● Qiagen N.V is one of the quiet giants of molecular diagnostics, and its shares have been living up to a reputation for steadiness, trading around the low-$40s in September 2026 with little day-to-day drama.

A modest uptick in a rare-disease micro-cap can mask a company at a genuine inflection point. Quince Therapeutics, Inc (NASDAQ: QNCX) edged higher in its latest session, but the more important story sits in its pipeline: a late-stage program aimed at a devastating pediatric …